Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents

被引：24

作者：

Ma, Zhen ^{[1
]}

Pan, Youlu ^{[1
]}

Huang, Wenhai ^{[1
]}

Yang, Yewei ^{[1
]}

Wang, Zunyuan ^{[1
]}

Li, Qin ^{[1
]}

Zhao, Yin ^{[1
]}

Zhang, Xinyue ^{[1
]}

Shen, Zhengrong ^{[1
]}

机构：

[1] Zhejiang Acad Med Sci, Inst Mat Med, Hangzhou 310013, Zhejiang, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 01期

关键词：

Pirfenidone; Derivatives; Antifibrotic; IPF; p38; IDIOPATHIC PULMONARY-FIBROSIS; DESIGN; ALPHA;

D O I：

10.1016/j.bmcl.2013.11.038

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A total of 24 pirfenidone derivatives were designed, synthesized and evaluated for their inhibitory activity against the human lung fibroblast cell line MRC-5. These compounds showed the remarkable proliferation inhibition against MRC-5 compared to pirfenidone as the positive control. The possible mechanism of this kind of derivatives as antifibrotic agents was explored. The molecular docking and p38 binding affinity assays demonstrated that the antifibrotic potential of the pirfenidone derivatives was possibly through the inhibition of p38 MAPK signaling pathway. The data from this study suggested that p38 might be a potential therapeutic target for the new generation antifibrotics. All the pirfenidone derivatives are reported here for the first time. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：220 / 223

页数：4

共 19 条

[1]

[Anonymous], 2012, ADP GLOTM KIN ASS IN

[2] Pirfenidone In Idiopathic Pulmonary Fibrosis [J].

Carter, Natalie J. .

DRUGS, 2011, 71 (13) :1721-1732

[3] Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents [J].

Chen, Jun ;

Lu, Miao-Miao ;

Liu, Bin ;

Chen, Zhuo ;

Li, Qian-Bin ;

Tao, Li-Jian ;

Hu, Gao-Yun .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (06) :2300-2302

[4] Pirfenidone treatment of idiopathic pulmonary fibrosis [J].

Gan, Ye ;

Herzog, Erica L. ;

Gomer, Richard H. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 :39-47

[5] Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration [J].

Giri, SN ;

Wang, QJ ;

Xie, Y ;

Lango, J ;

Morin, D ;

Margolin, SB ;

Buckpitt, AR .

BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (05) :203-211

[6] Effects of three anti-TNF-α drugs:: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-a associated with the cell in vitro [J].

Grattendick, K. J. ;

Nakashima, J. M. ;

Feng, L. ;

Giri, S. N. ;

Margolin, S. B. .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (05) :679-687

[7]

Karl K, 2009, [No title captured], Patent No. [20090318455 A1, 20090318455, 20090318455A1]

[8] Inhibition of p38 MAP kinase as a therapeutic strategy [J].

Lee, JC ;

Kumar, S ;

Griswold, DE ;

Underwood, DC ;

Votta, BJ ;

Adams, JL .

IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :185-201

[9] Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts [J].

Lin, Qing ;

Fang, Li-Ping ;

Zhou, Wei-Wei ;

Liu, Xin-Min .

EXPERIMENTAL LUNG RESEARCH, 2010, 36 (02) :120-128

[10] Design, Synthesis and Antifibrotic Activities of Carbohydrate-Modified 1-(Substituted aryl)-5-trifluoromethyl-2(1H) Pyridones [J].

Lou, Qinghua ;

Meng, Xiangbao ;

Lao, Zhiqi ;

Xuan, Lingling ;

Bai, Jinye ;

Hou, Qi ;

Hu, Gaoyun ;

Luo, Renna ;

Tao, Lijian ;

Li, Zhongjun .

MOLECULES, 2012, 17 (01) :884-896

← 1 2 →